Health New England seeks to reduce hemophilia costs
Courtesy
Arizona-based Magellan Health is partnering with Health New England on a program aimed at reining in costs and improving care for patients with hemophilia.
Springfield-based Health New England, a nonprofit health plan with members in Massachusetts and Connecticut, is partnering with an Arizona pharmacy benefits manager to improve care and rein in costs associated with hemophilia patients.
The average annual cost for patients with severe hemophilia, a genetic blood clotting disorder, can exceed $250,000 per patient, and may be upward of $1 million for some patients, according to Magellan Health Inc. The company operates Magellan Rx Management, the pharmacy benefits manager division that is partnering with Health New England.
The program targets utilization of hemophilia drugs and medical benefits to analyze patient-bleed history and treatment patterns; standardize dosing and dispensing protocols; and update policies to encourage individual treatment plans based on patient-specific metabolic factors.
The program will be led by pharmacists, who will collaborate with hemophilia treatment providers and pharmacies throughout the drug delivery process to improve care coordination and ensure program goals are being met, Magellan said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments